JUN 18, 2019 10:21 AM PDT

Drug Compound May Treat Common Genetic Kidney Disease

WRITTEN BY: Nouran Amin

Researchers from the University of Sheffield in collaboration with Glasgow-based biotech company Mironid, have developed a new class of drugs for treating a common genetic kidney disease, autosomal dominant polycystic kidney disease (ADPKD),that results in kidney failure.

ADPKD is a result of a genetic fault that alters the normal development of kidney cells causing cyst formation leaving the affected individuals in dire need of life-saving treatments, such as dialysis or a kidney transplant. The cysts in ADPKD cells express higher than normal levels of cyclic AMP (or cAMP)—which can tells when to divide and secrete fluid.

Learn more about ADPKD:

With the newly developed compound, it can activate an enzyme called PDE4, which functions to break down cAMP. The breakdown of cAMP can suppress the progression of ADPKD. Demonstrating the effects of PDE4 on cell lines and patient tissues, researchers were able to confirm that when the Mironid compound activated PDE4, the growth of the cysts were suppressed.

"Drug development usually focuses on looking for ways to block molecular and chemical processes, not switch them on, so this is a rare mode of action. As a researcher, it's very exciting to be involved in the early stage development of a completely new class of drugs,” says Professor Albert Ong, a consultant nephrologist and professor of renal medicine. "It's also very heartening for me as a clinician since like most genetic diseases, ADPKD cannot be cured. This discovery gives me hope for the many patients I see in my clinics that there could be another effective new treatment in the future to keep the disease in check for much longer, either on its own or in combination with other drugs such as tolvaptan. I would love to think that ADPKD could one day be a disease that people can successfully manage throughout their natural lives, rather than one that could shorten their lives."

Findings were published in the journal Proceedings of the National Academy of Sciences (PNAS).

"This exciting publication highlights the innovative science behind our LoAc® PDE4 activator technology. These first-in-class small molecules have the potential to address unmet clinical need in Autosomal Dominant Polycystic Kidney Disease (ADPKD), and potentially have further utility across different therapeutic areas where unbalanced cellular signaling drives disease progression. Looking to the future, we are excited and enthusiastic in our continued collaboration to translate this novel approach into real therapeutic benefit,” says Dr. David Henderson, Mironid’s senior investigator.

Source: University of Sheffield

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 15, 2021
Drug Discovery & Development
Magic Mushroom Therapy and Antidepressants Produce Similar Results
APR 15, 2021
Magic Mushroom Therapy and Antidepressants Produce Similar Results
In recent years, psilocybin (the psychoactive ingredient in 'magic mushrooms') has gained increasing amounts of ...
JUN 04, 2021
Drug Discovery & Development
Scientists Identify 90 Drugs that Could be Repurposed to Fight COVID-19
JUN 04, 2021
Scientists Identify 90 Drugs that Could be Repurposed to Fight COVID-19
Researchers from The Scripps Research Institute in California have identified 90 drugs that could be repurposed for trea ...
JUN 10, 2021
Plants & Animals
Antibiotics Fight Mysterious Coral Disease
JUN 10, 2021
Antibiotics Fight Mysterious Coral Disease
Coral reefs besieged by climate change and pollutants have a new line of defense against disease-an antibiotic commonly ...
JUN 17, 2021
Drug Discovery & Development
New COVID Drug Reduces Deaths in Patients with no Antibodies
JUN 17, 2021
New COVID Drug Reduces Deaths in Patients with no Antibodies
US drugmaker, Regeneron, in a partnership with Oxford University, has found that its new drug is capable of reducing COV ...
JUN 18, 2021
Drug Discovery & Development
FDA Approves First New Drug Since 2014 for Weight-loss
JUN 18, 2021
FDA Approves First New Drug Since 2014 for Weight-loss
A new medication called ‘Wegovy’ produced by Novo Nordisk has been approved by the Food and Drug Administrat ...
JUN 24, 2021
Immunology
Gut-Healing Stem Cells to Treat HIV Infections
JUN 24, 2021
Gut-Healing Stem Cells to Treat HIV Infections
A new study has revealed how stem cells can be used to amplify immune responses to HIV, the virus that causes AIDS. The ...
Loading Comments...